Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25325268 | 0.87 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL25322077 | 0.80 | — | — | |
| SCHEMBL30765145 | 0.76 | RECQL (0.34) | ALDH1A1LMNAHPGDTSHRMAPK1 | |
| SCHEMBL3768772 | 0.76 | RECQL (0.34) | ALDH1A1LMNAHPGDTSHRMAPK1 | |
| SCHEMBL28026930 | 0.75 | NOS3 (0.36) | ALDH1A1LMNAHPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL25318175 | 0.73 | SMN1; SMN2 (0.37) | ALDH1A1LMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL29844799 | 0.73 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL23489752 | 0.73 | RECQL (0.33) | ALDH1A1LMNAHPGDTSHRMAPK1 | |
| SCHEMBL25323256 | 0.72 | ATR (0.44) | ALDH1A1HPGDTSHRMAPK1L3MBTL1 | |
| SCHEMBL18572723 | 0.72 | PTPN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | ALDH1A1 79/4885LMNA 823/4885HPGD 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.